Retatrutide Phase 2 Data: A Deep Dive into the NEJM 2023 Trial

The published trial was a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted at multiple sites in the United States. The primary objective was to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Retatrutide in adults with overweight or obesity — a standard Phase 2 design for a metabolic compound.

The study enrolled 338 adults with a BMI (body mass index — a weight-to-height ratio (kg/m²) used as a population-level proxy for adiposity — a standard inclusion criterion for metabolic intervention trials) of 27 to 50 kg/m². Participants were randomized to one of six groups: five active dose groups (1 mg, 2 mg, 4 mg, 8 mg, and 12 mg weekly doses) and one placebo group. The 48-week treatment period was followed by a 5-week follow-up period.

Dose escalation protocols were used to minimize GI side effects: participants started at lower doses and escalated to their target dose over 8 to 20 weeks depending on the dose group. This stepped escalation is standard for GLP-1 class compounds to manage the nausea and vomiting that occur at the onset of treatment.

The primary endpoint was change in body weight from baseline (expressed as percentage of initial body weight at 48 weeks — the standard primary endpoint for metabolic pharmacology trials and the measure used in STEP trials for semaglutide). The results across dose groups showed a clear dose-response relationship.

At 48 weeks, the placebo group showed a mean body weight change of approximately −1.6%. The active dose groups showed: 1 mg: −8.7%, 2 mg: −17.1%, 4 mg: −17.5%, 8 mg: −22.8%, 12 mg: −24.2%. The between-group differences versus placebo were all statistically significant (p < 0.001 for all active doses).

The 12 mg dose group achieved mean body weight reduction of 24.2% at 48 weeks — a number that substantially exceeded the approximately 15% documented in the semaglutide STEP 1 trial at 68 weeks and the approximately 20.9% documented in tirzepatide trials at 72 weeks. The direct comparison caveat: these are different trials with different populations, durations, and baseline characteristics. Head-to-head data does not exist.

Secondary endpoints included multiple metabolic parameters. Published data showed statistically significant improvements in waist circumference, blood pressure, fasting glucose, hemoglobin A1c (HbA1c — the standard long term blood glucose control measure), triglycerides, and HDL cholesterol in the active dose groups compared to placebo.

Body composition analysis showed that the weight lost in Retatrutide-treated subjects was predominantly fat mass — specifically including visceral fat — with relative preservation of lean mass (muscle). The ratio of fat mass lost to lean mass lost in the published data was favorable compared to historical data for other weight loss approaches, though the comparison is approximate given the different measurement methods used across studies.

Cardiometabolic risk factors improved substantially across multiple markers simultaneously — reflecting that the weight loss achieved was sufficient to produce clinically meaningful changes in the multiple components of metabolic syndrome. This multi-factor improvement is mechanistically expected given the magnitude of fat mass reduction and the direct effects of GIP and glucagon receptor agonism on metabolic parameters.

The most common adverse events were GI-related: nausea (occurring in 38 to 71% of subjects across dose groups versus 14% placebo), vomiting (12 to 43% versus 1%), diarrhea (16 to 34% versus 9%), and constipation (9 to 24% versus 7%). These rates were consistent with or slightly higher than those reported for semaglutide and tirzepatide at comparable treatment phases.

GI adverse events were predominantly mild to moderate in severity and were most frequent during the dose-escalation period, declining as subjects reached and maintained their target dose. Discontinuation due to adverse events occurred in 6 to 16% of subjects across dose groups versus 1% in placebo — consistent with the GI tolerability challenge of this compound class.

Serious adverse events occurred in a comparable proportion of active versus placebo groups in most categories, without signal for any compound-specific serious risk at the sample size of this Phase 2 trial. Gallbladder-related events (cholelithiasis — gallstone formation, a known risk with rapid weight loss of any cause) appeared at a slightly higher rate in higher-dose active groups. Cardiac rate effects — bradycardia — were documented at a slightly higher rate in some active groups, attributed to the GLP-1 receptor's cardiac effects.

One of the theoretical concerns about including glucagon receptor agonism in a triple-receptor compound was the potential for hyperglycemia — glucagon raises blood glucose, and adding glucagon receptor agonism to GLP-1/GIP agonism could theoretically produce offsetting or even net glucose-raising effects in some metabolic states.

The published Phase 2 data addressed this concern directly: in subjects without type 2 diabetes at baseline, mean fasting glucose did not increase — it decreased modestly in most dose groups. In subjects with diabetes at baseline, HbA1c decreased substantially. The glucagon receptor component did not produce problematic hyperglycemia in the studied population at studied doses.

The proposed interpretation is that the GLP-1-driven glucose-dependent insulin secretion overcomes the glycogenolytic effects of glucagon receptor activation under the metabolic conditions of this study population. Whether this balance holds in populations with more severe insulin deficiency (advanced type 2 diabetes with significant beta cell loss) is an important question that Phase 3 trials will address.

This Phase 2 trial, rigorous and well-designed as it is, cannot answer several important questions. Duration: 48 weeks of treatment data does not establish what happens with longer treatment. Does the weight loss continue, plateau, or partially reverse with chronic treatment? Are there adverse effects that only emerge after years of triple receptor agonism? Phase 2 cannot answer these questions.

The population studied was predominantly otherwise healthy overweight and obese adults without type 2 diabetes (approximately 70% of enrolled subjects). Efficacy and safety in populations with type 2 diabetes, cardiovascular disease, liver disease, kidney disease, or other comorbidities requires separate study. Phase 3 trials are specifically designed to include a broader population.

Long term outcomes — cardiovascular events, mortality, effects on lean mass and bone density, effects on beta cell function — require years of follow-up and thousands of subjects. Phase 2 provides no information on these outcomes. The Phase 3 program, which is ongoing as of this publication, is designed to address these questions.

For the metabolic research community, the Phase 2 Retatrutide data represented a new benchmark. Published commentary following the NEJM publication noted that the magnitude of body weight reduction in the highest dose group — approaching 25% — approached the range historically achievable only through bariatric surgery, and exceeded what had been believed pharmacologically achievable through incretin-based approaches.

This recalibration of expectations has influenced the design of subsequent metabolic research programs across the field. Multiple additional triple and quadruple receptor agonists are in development following the demonstration that glucagon receptor addition to GLP-1/GIP does not produce net metabolic harm and appears to amplify beneficial outcomes.

For researchers studying Retatrutide specifically, the Phase 2 data provides the best available characterization of human pharmacology at specific doses and durations. Protocol designs referencing this compound should be anchored in this data — in terms of dose range, onset timeline, expected effect magnitude, and anticipated adverse event profile.

Researchers studying triple receptor agonism and metabolic pharmacology can review Retatrutide product specifications at Blackwell BioLabs. All batches are third party tested with HPLC purity confirmation and mass spectrometry identity verification on every lot.